Clinical trials: COPD - Chronic Obstructive Pulmonary Disease
- Condition COPD - Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
Chronic Obstructive Pulmonary Disease (COPD), Alpha1-Antitrypsin Deficiency
A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema
The main purpose of this study is to evaluate the efficacy of RYMPHYSIA [Alpha1-Proteinase Inhibitor (Human)] compared to another available alpha-1 proteinase Inhibitor (A1PI) in adults with A1PI deficiency and COPD-emphysema.
- Trial name
- NCT05466747
- Testing
- RYMPHYSIA, Another Available A1PI
- Sponsor
- Takeda
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)
Trial will include 40 subjects and consists of 3 visits: Screening, Treatment and Follow up. A euglycemic clamp procedure and Technosphere®/Insulin (T/I) administration will occur at Visit 2 for both COPD and non COPD subjects.
- Trial name
- NCT01021891
- Testing
- Technosphere®/Insulin
- Where
- 5 sites in United States, Austria and 2 more
- Volunteers
- 39 people
- Sponsor
- Mannkind Corporation
COPD
Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to determine the safety and tolerability of single doses of QAB149 up to 3000 µg delivered via a single-dose, dry powder inhaler in patients with mild to moderate COPD.
- Trial name
- NCT00129831
- Testing
- QAB149
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease
Prevalence Study and Regular Practice Among General Practitioners in Populations at Risk of Chronic Obstructive Pulmonary Disease (COPD) in Latin America
PUMA is an observational, multicentre, multinational, cross-sectional study with primary care physicians (primary care, general and family physicians).
- Trial name
- PUMA PROJECT (NCT01493544)
- Where
- 18 sites in Argentina, Colombia and 2 more
- Volunteers
- 1,907 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, Bronchitis
Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate and compare the efficacy of arformoterol twice a day and tiotropium once a day (dosed sequentially) versus tiotropium once a day alone in subjects with Chronic Obstructive Pulmonary…
- Conditions
- Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
- Trial name
- NCT00424528
- Testing
- Arformoterol Tartrate Inhalation Solution, Tiotropium, Arformoterol and Tiotropium
- Where
- 28 sites in United States
- Volunteers
- 235 people
- Sponsor
- Sumitomo Pharma America, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Aclidinium/Formoterol Fixed Combination Dose Finding Study
The study seeks to determine the optimal dose of the Aclidinium/Formoterol combination for investigation in Phase III clinical trials
- Trial name
- NCT00626522
- Testing
- Aclidinium bromide and formoterol
- Where
- 9 sites in Australia, Czechia and 2 more
- Volunteers
- 808 people
- Sponsor
- AstraZeneca
Lung Diseases, Pulmonary Disease, Chronic Obstructive
An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)
This is a study to evaluate the effectiveness and tolerability of a once-daily oral medication (MK-0873) for the treatment of COPD (chronic obstructive pulmonary disease) to determine whether the study drug leads to an…
- Trial name
- NCT00132730
- Testing
- MK-0873 2.5 mg, MK-0873 1.25 mg, MK-0873 0.75 mg
- Volunteers
- 604 people
- Sponsor
- Merck Sharp & Dohme LLC
COPD
Impact of Morning Symptoms in Clinical Control of Chronic Obstructive Pulmonary Disease (COPD)
Observational study to know the Impact of morning symptoms in clinical control of COPD patients. 1200 patients will be included by General practitioners (GPs) and pneumologists.
- Trial name
- IMPAEPOC (NCT01266395)
- Where
- 52 sites in Spain
- Volunteers
- 1,268 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1b Study of PUR1800 in Patients With COPD
This is a randomised, placebo-controlled, double-blind 3-way crossover study in which PUR1800, or placebo is dosed daily for 14 consecutive days in adult subjects with stable COPD over three discrete TPs.
- Trial name
- NCT04759807
- Testing
- PUR1800 250 ug, PUR1800 500 ug
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Pulmatrix Inc.
Pulmonary Disease, Chronic Obstructive
Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities
The objective of the present Post Marketing Surveillance Study (PMS) study is to evaluate safety and effectiveness of tiotropium bromide (Spiriva®) 18 µg once daily in 5,000 patients with COPD of varying severities over 8 weeks.
- Trial name
- NCT00621582
- Volunteers
- 4,918 people
- Sponsor
- Boehringer Ingelheim
COPD, Pulmonary Hypertension
An Open-Label Study to Evaluate the Safety and Efficacy of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease
A 3-month open label study to evaluate the safety and efficacy of PRX-08066 in patients with pulmonary hypertension and COPD.
- Trial name
- NCT00677872
- Testing
- PRX-08066
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Epix Pharmaceuticals, Inc.
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
Lung Disease, Chronic Obstructive, Lung Disease, Interstitial
Diagnosis of Cardio-Pulmonary Pathology Using Transthoracic Parametric Doppler (TPD)
This is a study that seeks to characterize data obtained from patients with a variety of lung diseases using ultrasound signals obtained from the lung tissue.
- Conditions
- Lung Disease, Chronic Obstructive, Lung Disease, Interstitial, Asthma, Sarcoidosis
- Trial name
- NCT01361139
- Where
- 2 sites in Israel
- Volunteers
- 500 people
- Sponsor
- Echosense Ltd.
Chronic Obstructive Pulmonary Disease
A Study of the Inflammatory Pathways Associated With Chronic Obstructive Pulmonary Disease Exacerbations
The purpose of this study is to observe how the inflammatory pathways differ in subjects with chronic obstructive pulmonary disease (COPD) during an acute exacerbation of COPD (AECOPD).
- Trial name
- NCT01337661
- Where
- Ireland
- Volunteers
- 26 people
- Sponsor
- MedImmune LLC
Pulmonary Disease, Chronic Obstructive (COPD)
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.
- Trial name
- NCT07039669
- Testing
- 611
- Where
- 4 sites in China
- Volunteers
- 594 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to evaluate the effect of tiotropium on gross muscular efficiency
- Trial name
- NCT02172794
- Testing
- Tiotropium, Salmeterol
- Volunteers
- 48 people
- Sponsor
- Boehringer Ingelheim
COPD, Chronic Obstructive Pulmonary Disease
Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD
The symptoms associated with COPD include overproduction of mucus and inflammation in the lungs. Overproduction of mucus results in impaired lung function and it encourages bacterial growth and associated COPD exacerbations.
- Trial name
- BREATH-1 (NCT00648245)
- Testing
- BIO-11006 Inhalation Solution, BIO-11006
- Where
- 14 sites in United States
- Volunteers
- 172 people
- Sponsor
- BioMarck Pharmaceuticals, Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)
This study compared the safety and efficacy of indacaterol 150 µg taken once daily (o.d.) versus salmeterol 50 µg taken twice daily (b.i.d) in patients 40 years old or older with chronic obstructive pulmonary disease.
- Trial name
- INSIST (NCT00821093)
- Testing
- Indacaterol 150 µg, Salmeterol 50 µg
- Where
- 144 sites in United States, Czechia and 6 more
- Volunteers
- 1,123 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.
The present trial is conducted to further assess the efficacy by means of serial spirometry, safety and tolerability of three doses of aclidinium bromide administered twice a day compared to previously approved BID drug…
- Trial name
- NCT01120093
- Testing
- Aclidinium bromide 100 μg bid, Aclidinium bromide 200 μg bid, Aclidininum bromide 400 μg bid
- Where
- 11 sites in Belgium, Germany
- Volunteers
- 79 people
- Sponsor
- AstraZeneca
Obesity Hypoventilation Syndrome, Obstructive Sleep Apnea
Simplus and Eson Non-Invasive Ventilation (NIV) Evaluation - Germany
This investigation is designed to evaluate the performance, comfort and ease of use of the Simplus and Eson masks amongst NIV patients who are currently on Bi-level therapy
- Conditions
- Obesity Hypoventilation Syndrome, Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, Neuromuscular Disease
- Trial name
- NCT02726048
- Testing
- Simplus/Eson
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- Fisher and Paykel Healthcare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.